Business Context and Reporting Period
Company: Geron Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2010
Business Overview: Geron is a biopharmaceutical company developing first-in-class therapies for cancer and chronic degenerative diseases. Its primary platforms target the enzyme telomerase (oncology) and utilize human embryonic stem cells (hESCs) for regenerative medicine. The company has no approved products and relies on research and development funding, licensing agreements, and collaborations.
Key Financial Metrics
| Metric (in thousands) | Q1 2010 | Q1 2009 |
|---|---|---|
| Total Revenues | $918 | $444 |
| Net Loss | $(16,640) | $(16,811) |
| Net Loss Per Share (Basic & Diluted) | $(0.18) | $(0.20) |
| Cash and Cash Equivalents | $35,900 | $109,348 (Beginning of period) |
| Total Cash, Restricted Cash, and Marketable Securities | $166,537 | $167,100 (Dec 31, 2009) |
| Accumulated Deficit | $(593,907) | $(577,267) |
| Net Cash Used in Operating Activities | $(9,365) | $(9,290) |
| Net Cash Provided by Financing Activities | $9,992 | $46,654 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 107% to $918,000 from $444,000. This was driven by $225,000 in revenue from collaborative agreements (specifically with GE Healthcare UK Limited) and an increase in license fees and royalties to $693,000 from $444,000.
- Operating Expenses: Total operating expenses increased slightly to $17.4 million from $17.1 million. Research and Development (R&D) expenses decreased by $226,000 due to reduced manufacturing and clinical trial costs for completed Phase I/II trials, partially offset by increased preclinical costs and stock-based compensation. General and Administrative (G&A) expenses increased by $472,000 due to higher legal costs and stock-based compensation.
- Interest Income: Interest and other income decreased significantly to $202,000 from $525,000, attributed to lower interest rates and reduced cash balances.
- Financing Activity: The company raised approximately $10.0 million in gross proceeds in January 2010 through the exchange of warrants and the sale of common stock to institutional investors.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management estimates existing capital resources, interest income, and an equipment financing facility will fund operations through at least December 2011. However, substantial additional capital will be required for future clinical trials and development.
- Revenue Expectations: The company expects to recognize $525,000 in revenue for the remainder of 2010 and $350,000 in 2011 related to existing deferred revenue. No revenues are expected thereafter from current agreements.
- Clinical Pipeline Status:
- Imetelstat (Telomerase Inhibitor): Planning to advance to Phase II trials in four malignancies in 2010.
- GRNVAC1 (Cancer Vaccine): Phase II trial in Acute Myelogenous Leukemia is complete; awaiting results.
- GRNOPC1 (hESC Therapy): Clinical trial for spinal cord injury is currently on clinical hold by the FDA. The company is in discussions to resolve the hold.
- Key Risks:
- Regulatory Uncertainty: Delays in FDA approvals or the inability to lift the clinical hold on GRNOPC1 could materially harm the business.
- Capital Needs: Failure to raise additional capital could force the curtailment of operations.
- Intellectual Property: Ongoing patent oppositions and reexaminations (e.g., regarding hESC patents in Europe and the US) create uncertainty regarding proprietary rights.
- Manufacturing Costs: High manufacturing costs for oligonucleotides and cell therapies may impact future profitability.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $166.5 million in liquid assets to fund operations through the projected December 2011 date, considering the high burn rate of clinical trials.
- GRNOPC1 Clinical Hold: Monitor the status of discussions with the FDA regarding the clinical hold on the spinal cord injury therapy, as this is a critical near-term milestone.
- Revenue Sustainability: Assess the reliance on the GE Healthcare collaboration and the limited visibility of future revenue beyond 2011.
- Patent Litigation: Review the outcomes of ongoing patent oppositions in Europe and reexaminations in the US, particularly regarding hESC technologies.
- Stock-Based Compensation: Note the significant non-cash expense ($3.1 million in Q1 2010) and its impact on reported net loss versus cash burn.